
Celularity Inc. – NASDAQ:CELUW
Celularity stock price today
Celularity stock price monthly change
Celularity stock price quarterly change
Celularity stock price yearly change
Celularity key metrics
Market Cap | 47.84M |
Enterprise value | 34.51M |
P/E | -0.08 |
EV/Sales | 1.84 |
EV/EBITDA | -9.21 |
Price/Sales | 0.53 |
Price/Book | 0.06 |
PEG ratio | N/A |
EPS | -10.18 |
Revenue | 14.78M |
EBITDA | -120.27M |
Income | -181.40M |
Revenue Q/Q | -8.44% |
Revenue Y/Y | -20.93% |
Profit margin | -76.37% |
Oper. margin | -310.32% |
Gross margin | -2.01% |
EBIT margin | -310.32% |
EBITDA margin | -813.35% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCelularity stock price history
Celularity stock forecast
Celularity financial statements
Dec 2022 | 4.12M | 24.43M | 591.77% |
---|---|---|---|
Mar 2023 | 3.93M | -64.01M | -1626.86% |
Jun 2023 | 2.93M | -47.94M | -1632.03% |
Sep 2023 | 3.78M | -93.87M | -2479.56% |
Dec 2022 | 401066000 | 202.16M | 50.41% |
---|---|---|---|
Mar 2023 | 362416000 | 206.78M | 57.06% |
Jun 2023 | 246419000 | 127.91M | 51.91% |
Sep 2023 | 157192000 | 126.94M | 80.76% |
Dec 2022 | -29.58M | -779K | 1.68M |
---|---|---|---|
Mar 2023 | -14.99M | -3.20M | 12.75M |
Jun 2023 | -11.02M | -31K | 5.61M |
Sep 2023 | -8.32M | -228K | 5.73M |
Celularity alternative data
Aug 2023 | 225 |
---|---|
Sep 2023 | 225 |
Oct 2023 | 225 |
Nov 2023 | 225 |
Dec 2023 | 225 |
Jan 2024 | 225 |
Feb 2024 | 225 |
Mar 2024 | 225 |
Apr 2024 | 225 |
May 2024 | 225 |
Jun 2024 | 225 |
Jul 2024 | 225 |
Celularity other data
Period | Buy | Sel |
---|---|---|
Nov 2022 | 90000 | 0 |
-
What's the price of Celularity stock today?
One share of Celularity stock can currently be purchased for approximately $0.06.
-
When is Celularity's next earnings date?
Unfortunately, Celularity's (CELUW) next earnings date is currently unknown.
-
Does Celularity pay dividends?
No, Celularity does not pay dividends.
-
How much money does Celularity make?
Celularity has a market capitalization of 47.84M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26.68% to 22.77M US dollars.
-
What is Celularity's stock symbol?
Celularity Inc. is traded on the NASDAQ under the ticker symbol "CELUW".
-
What is Celularity's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Celularity?
Shares of Celularity can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Celularity have?
As Jul 2024, Celularity employs 225 workers.
-
When Celularity went public?
Celularity Inc. is publicly traded company for more then 4 years since IPO on 19 Jul 2021.
-
What is Celularity's official website?
The official website for Celularity is celularity.com.
-
Where are Celularity's headquarters?
Celularity is headquartered at 170 Park Avenue, Florham Park, NJ.
-
How can i contact Celularity?
Celularity's mailing address is 170 Park Avenue, Florham Park, NJ and company can be reached via phone at +90 87682170.
Celularity company profile:

Celularity Inc.
celularity.comNASDAQ
120
Biotechnology
Healthcare
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Florham Park, NJ 07932
CIK: 0001752828
ISIN: US1511901134
CUSIP: 151190113